STOK Stoke Therapeutics
- 12.010
- +0.410+3.53%
- 12.050
- +0.040+0.33%
Stoke Therapeutics News
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Stoke Therapeutics Price Target Cut to $20.00/Share From $21.00 by Canaccord Genuity
Stoke Therapeutics Price Target Cut to $20.00/Share From $21.00 by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the Stoke Therapeutics (STOK.US) rating, adjusted from buy to buy rating, and adjusted the target price from $21.00 to $20.00.
Canadian Investment Banking Group: Maintaining the Stoke Therapeutics (STOK.US) rating, adjusted from buy to buy rating, and adjusted the target price from $21.00 to $20.00.
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Stoke Therapeutics with a Buy and maintains $35 price target.
Buy Rating for Stoke Therapeutics With Adjusted Price Target Amid Regulatory and Developmental Progress
Stoke Therapeutics | 10-Q: Quarterly report
Analyst Expectations For Stoke Therapeutics's Future
Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Stoke Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 82.27% Needham → $22 Reiterates Buy → Buy 04/11/2024 82.27% Needham → $22 Reiterates Buy → Buy
Optimistic Outlook: Buy Recommendation for Stoke Therapeutics Amidst Strategic Progress and Anticipated Clinical Milestones
Stoke Therapeutics Inc Q1 Loss Increases, but Beats Estimates
Stoke Therapeutics (STOK.US): The 2024 Q1 financial report achieved revenue of US$4.216 million, with a previous value of US$5.512 million, with an expected value of US$3.21 million; earnings per share were -0.57 dollars, previous value of -0.53 dollars,
Stoke Therapeutics (STOK.US): The 2024 Q1 financial report achieved revenue of US$4.216 million, with a previous value of US$5.512 million, with an expected value of US$3.21 million; earnings per share were -0.57 dollars, previous value of -0.53 dollars, and expected value of -0.61 dollars.
Stoke Therapeutics Q1 2024 GAAP EPS $(0.57) Beats $(0.61) Estimate, Sales $4.216M Beat $3.214M Estimate
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.61) by 6.56 percent. The company reported quarterly sales of $4.216 mi
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M
07:01 AM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M
Stoke Therapeutics 1Q Loss $26.4M >STOK
Stoke Therapeutics 1Q Loss $26.4M >STOK
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company's proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
Stoke Therapeutics(STOK.US) Officer Sells US$113.65K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Ticho Barry sold 10,000 shares of common stock on May 1, 2024 at an average price of $11.3653 for a total value of $113.65K.Source: Announcement What is statement
Stoke Therapeutics Chief Financial Officer Stephen Tulipano Resigns
By Colin Kellaher Stoke Therapeutics on Monday said its chief financial officer, Stephen Tulipano, has resigned, effective May 7. The Bedford, Mass., biotechnology company said Thomas Leggett, who m
Analysis
Price Target
No Data
